b u r n s 3 6 ( 2 0 1 0 ) 1 1 7 2 -1 1 8 4 a b s t r a c t Background: Topical antimicrobials are employed for prophylaxis and treatment of burn wound infections despite no established susceptibility breakpoints, which are becoming vital in an era of multidrug-resistant (MDR) bacteria. We compared two methods of determining topical antimicrobial susceptibilities. Methods: Isolates of Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus (MRSA), extended spectrum beta-lactamase (ESBL) producing Klebsiella pneumoniae, and Acinetobacter baumanii-calcoaceticus (ABC) from burn patients were tested using broth microdilution and agar well diffusion to determine minimum inhibitory concentrations (MICs) and zones of inhibition (ZI). Isolates had systemic antibiotic resistance and clonality determined. MDR included resistance to antibiotics in three or more classes.
Introduction
Improvements in burn care have led to longer survival but have extended hospital stays. Patients who perish after surviving the initial burn insult and resuscitation are most likely to die from infectious complications [1] . Burn patients are relatively immunosuppressed and are at high risk of infections, in particular with nosocomially-acquired multi-drug-resistant (MDR) organisms [2] . Burns result in loss of the first line of immunologic defense, the skin, and burn eschar is avascular. This can result in an increased risk for bacterial colonization and subsequent invasion, which can ultimately result in burn wound infection. This may be difficult to control due to difficulty immune cells and systemic antibiotics have in arriving to an avascular site [3] . Burn wound infections are a significant and serious complication occurring after thermal injury. Though the rate of burn wound infections has decreased, burn wound sepsis remains a substantial source of infection in this population [4] . Improvements in burn wound care, such as early excision and grafting, have resulted in decreased mortality [5] . Early excision and grafting is the standard of care at specialized burn centers in the United States. The benefit of topical antimicrobials, however, is that they can be used at all levels of care, even when surgery for excision and grafting is not available. Topicals such as honey have been in use since antiquity, and others for decades [4] [5] [6] [7] [8] [9] [10] [11] . There are both animal studies and clinical studies that provide data about the morbidity and mortality benefits associated with use of various topical antimicrobial agents in the prevention and treatment of burn wound infections [5, [12] [13] [14] [15] [16] [17] . Another benefit of topical agents is that they can be delivered directly to the site of colonization or infection and can be used for both the prophylaxis and treatment of burn wound infections [18] . Agents such as silver sulfadiazine, silver nitrate, mupirocin, honey, mafenide acetate, and neomycin have been in use for years with variable amounts of objective data available to support their use ( Table 1) .
Though we have in vitro data about the topical antibiotics' general spectrum of activity, there are no established clinical breakpoints to determine whether an isolate is susceptible to a particular agent at concentrations expected at the wound surface. Bacteria with resistance to multiple systemic antimicrobials are increasing in prevalence worldwide, which raises concern for a subsequent increase in resistance to topical agents. The potential for resistant isolates makes choosing empiric systemic antimicrobial therapy in the burn unit more challenging and may reduce the number of available treatment options. Thus, the possibility of using topical agents for prophylaxis and treatment of burn wound infections is appealing, in particular given the ability to apply topical agents directly at the site of infection, avoiding potential systemic toxicities and the risk of systemic antibiotics not arriving through avascular tissue to the site of infection. However, some previous studies have already noted concern for resistance to topical agents as well to include emerging resistance of staphylococci to mupirocin and of Pseudomonas aeruginosa to silver sulfadiazine (Table 1 ) [9, [18] [19] [20] [21] .
Prior studies assessing topical agent antimicrobial resistance profiles have used agar well diffusion and broth microdilution methods with data indicating an increase in resistance of MDR pathogens to topical antimicrobials as compared to non-MDR pathogens [8, [22] [23] [24] . However, there are limited data comparing strain variability and systemic antimicrobial resistance to topical antimicrobial activity tested by various methods.
With MDR bacteria on the rise we designed this study to compare selected bacterial isolates against various topical antimicrobial agents using two methods, broth microdilution and agar well diffusion, in conjunction with phenotypic and genotypic testing to evaluate for clonal differences in activity and correlation with systemic resistance profiles and topical agent activity.
Methods

Bacterial isolates
A collection of bacterial isolates were obtained from patients admitted to the US Army Institute of Surgical Research (USAISR) Burn Center. The USAISR Burn Center is a 40-bed unit located within Brooke Army Medical Center that serves Department of Defense beneficiaries worldwide and the civilian population from within the southern Texas regional trauma system. Standard burn patient care includes resuscitation and stabilization upon arrival with early burn wound excision and skin grafting. Vancomycin and amikacin are administered routinely peri-operatively and various topical antimicrobials are used to include silver sulfadiazine, mafenide acetate, silver nitrate solution, and silver-impregnated dressings. The choice of the specific topical agent used is at staff discretion. Aggressive infection control is practiced in the center to include individual patient rooms, use of contact precautions, and strictly enforced handwashing. The most common gram-negative pathogens recovered in our burn unit are Acinetobacter baumannii-calcoaceticus complex (ABC), extended-spectrum beta-lactamase (ESBL) producing Klebsiella pneumoniae, and P. aeruginosa, with methicillinresistant Staphylococcus aureus (MRSA) being a common gram-positive organism isolated. Isolates studied had been saved for performance improvement purposes and were stored in Microbank 1 Bacterial Preservation systems (Pro-Lab Diagnostics, Austin, TX) at À20 8C. The P. aeruginosa isolates were stored at room temperature on agar deeps. Isolates were passed twice on Trypticase TM Soy Agar with 5% Sheep Blood (TSA II) (BD Diagnostic) prior to use. Quality control (QC) bacteria (Escherichia coli ATCC 1 25922, Enterococcus faecalis ATCC 1 29212, P. aeruginosa ATCC 1 27853, and S. aureus ATCC 1 29213) were obtained from the American Type Culture Collection (Manassas, VA). The QC organisms were maintained and cultured in the same manner as the test organisms.
Antimicrobial susceptibility testing
Using the Phoenix Automated Microbiology System (Becton, Dickinson and Co., Franklin Lakes, NJ) standard systemic antibiotic profiles were determined [25]. For P. aeruginosa and ABC, we defined MDR as resistance to all antimicrobials tested in a group for 3 or more groups among the aminoglycosides, betalactams, carbapenems, and fluoroquinolones [26] . All of the K. pneumoniae isolates used in this study were ESBL-producing. All of the S. aureus isolates were methicillin-resistant. [8, 9] Gram-positive organisms especially Staphylococci and beta-hemolytic Streptococci [8] Inactive against most gramnegative organisms including P. aeruginosa [34] Minimal absorption Rare anaphylaxis and allergic contact dermatitis [9] Rare resistant S. aureus [9] None available
Medical grade honey
Variable antimicrobial activity among honeys collected from natural environments [7] Properties responsible for antimicrobial activity include high osmolarity, low pH (3.2-4.5), a thermolabile substance called inhibine, and production of hydrogen peroxide [7, 35] Also may have some antiinflammatory activity [36] Bactericidal against grampositive and gram-negative organisms including P. aeruginosa and MRSA [35, 37] Manages superficial bacteria but may also diffuse through skin to deeper tissues [36] Generally found to be soothing, pain-relieving, and nonirritating [36] May promote healing of burn wounds and reduce scarring [35] Food-grade honey is not a sterile product; may contain Bacillus spp. [38] Medical-grade honey needs to be filtered and gamma-irradiated Avoid use in patients with allergy to honey, bee products, or bee stings [36] No reported resistance [7] Honey helped burn wounds to heal earlier and with fewer complications than convention treatment (silver sulfadiazine) [35] Most data available is on Leptospermum spp. honey (Manuka)
Mafenide acetate (Sulfamylon) Inhibits nucleotide synthesis [8] Bacteriostatic against gramnegative organisms including P. aeruginosa and gram-positive organisms [13, 39] 11.1% cream, 5% solution Rapidly penetrates full thickness eschar making it effective in heavily colonized wounds and established burn wound infection [3, 5, 33] 11.1% concentration is painful when applied to the superficial partial-thickness burns with intact free nerve endings [3, 40] Can dry into a tenacious gum (neoeschar) that attaches to the wound requiring hydrotherapy to remove [41] 5% aqueous solution is less painful and does not leave a residue [42] Absorbed systemically with highest blood levels of mafenide and its metabolite (pcarboxybenzenesulfonamide) in 2nd-4th hour resulting in urinary alkalinization from carbonic anhydrase inhibition [43] Possible metabolic acidosis, especially in patients with pulmonary dysfunction such as atelectasis or pneumonia that limits respiratory compensation [14, 40, 44] Electrolyte disturbances [45] 7% incidence of hypersensitivity, usually a rash [5] Rapid absorption from the tissue requires twice daily application to keep levels high enough for bacterial inhibition [33] No resistance reported to P. aeruginosa [6] Some resistance described to Providencia [5] Mortality benefit in prevention of burn wound sepsis described in animal models [13] Reduction in mortality and the rate of invasive burn wound infections in patients from before the introduction of mafenide to after, particularly in patients with 40-79% TBSA in one study [5] and between 20 and 59% TBSA in another study [14, 15] Found to be the most effective topical agent against A. baumannii [18] Poor correlation between broth microdilution and agar well diffusion [23] b u r n s 3 6 ( 2 0 1 0 ) 1 1 7 2 -1 1 8 4
Mupirocin Pseudomonic acid, produced by Pseudomonas fluorescens [19] Inhibition of RNA and protein synthesis by targeting the isoleucine-binding site on the isoleucyl-transfer-RNA synthetase enzyme [9, 46, 47] Bactericidal at high concentrations (2% formulation) and after 24-36 h of exposure [46] Highly active against streptococci and staphylococci including MRSA [9] . Not active against enterococci Less effective against most gram-negative bacilli and anaerobes including K. pneumoniae and P. aeruginosa [19] No systemic absorption of mupirocin or its major metabolite (monic acid) has been detected with topical use in healthy volunteers or patients with epidermolysis bullosa [9, 46] Can penetrate eschar [48] Has been used successfully in the treatment of MRSA-infected burns wounds [49] Prolonged use may result in overgrowth of non-susceptible organisms, including fungi [9] Emergence of resistant staphylococci has been described worldwide [9, 19, 20] Possible mechanism of resistance is a transmissible plasmid [46] No cross resistance with other antibiotics [50] Application of mupirocin to burn wounds rapidly eradicated MRSA [48] Good correlation between broth microdilution and agar well diffusion [23] Neomycin Aminoglycoside produced by Streptomyces fradiae [51] Inhibition of protein synthesis at the 30S subunit of the bacterial ribosome [9] May also inhibit bacterial DNA polymerase
Gram-negatives except Pseudomonas aeruginosa and anaerobes such as Bacteroides spp. [51] Staphylococci, not Streptococci and gram-positive bacilli
May enhance reepithelialization in wound healing [34] Otoxicity and nephrotoxicity with systemic use. Absorption can occur through inflamed skin but is negligible through normal skin [9, 51] Allergic sensitization especially when ointment is used for prolonged time on inflamed or denuded skin [51] . Related to mast cell degranulation and histamine release [9] Resistant strains of E. coli, Klebsiella, and Proteus spp. may emerge [51] Transfer of neomycin resistance occurs in hospital-acquired isolates of S. aureus Resistance may be plasmid mediated, and resistance to other aminoglycosides can be transferred on the same plasmid [9] None available Polymyxin B Inhibits activity of endotoxins [52] Interacts with the outer membrane of the gramnegative cell wall and destroys bacterial membranes with a detergent-like mechanism [8, 52] Gram-negative organisms including P. aeruginosa [8] No activity against grampositive organisms or fungi [9] Little systemic absorption [9] No data available Resistant strains of A. baumannii are emerging [18] None available Silver nitrate Interferes with electron transport inhibiting cellular respiration and function [8, 17] Gram-negative and grampositive organisms including Pseudomonas spp. and S. aureus [8, 53] Some activity against Candida spp.
0.5% aqueous solution
Reduces nutritional and metabolic losses by decreasing evaporative water loss [3, 33, 54] Painless on application [33] Poor eschar penetration [3] so can be used for prophylaxis but not treatment of burn wound infections [55] Turns black upon contact with tissues and can stain linens [53, 54, 56, 57] Electrolyte disturbances due to leeching of cations across the wound into the hypotonic solution, ''sodium sink'' [3, 6, 20, 33, 40, 54] Aerobacter cloacae and some other gram-negative bacteria can convert the nitrate to nitrite causing methemoglobinemia [3] Problems with tissue irritation and delayed wound healing have been reported [3, 57] Acquired resistance is uncommon [33, 58] Resistance is often unstable and isolates can revert back to sensitive [59] Has been used in burn treatment since at least the 18th century, initially in a hardened form called lunar caustic [10] Reduced mortality in burned mice with P. aeruginosa infection by 30% [16] Application to >40% TBSA wounds delayed sepsis and reduced mortality from 81% to 33% [54] b u r n s 3 6 ( 2 0 1 0 ) 1 1 7 2 -1 1 8 4 Interferes with electron transport and nucleotide synthesis [8] Binds to bacterial cell membranes and cell wall, penetrates the cell, and denatures bacterial DNA and RNA resulting in inhibition of replication [9, 17] Bactericidal to gram-negative and gram-positive organisms including Pseudomonas spp. and S. aureus (MRSA) [3, 20] Some activity against Candida spp. and herpesviruses at high concentrations [9] Combination of the silver ion and sulfadiazine in a 1% water soluble cream introduced in 1968 [3] Painless on application [60] Accelerated deep dermal wound healing and reduced conversion rate of deep dermal wounds to full-thickness skin wounds [17] Delayed eschar separation [17] Poor eschar penetration Reversible granulocyte depression especially in >30% TBSA burns [3, 6, 9] . This occurs early in therapy (postburn day 2) and mainly affects mature neutrophils though has not been shown to increase risk of infectious complications [61] Not very effective in established infection due to minimal eschar penetration [49] Appears as a thick creamy exudates on the wound, which can be confused with pus [3, 53] Rare hypersensitivity reactions to sulfa moiety reported [33, 62] and rare hemolysis in setting of G6PD deficiency [21] Systemic absorption especially in more vascular partialthickness burns [21, 63] though an experimental model using radioactive silver sulfadiazine showed silver only in the skin and not in the blood/organs [53] Rare argyrosis [63] if silver levels are many times normal [21] Resistant to most Enterobacter cloacae and some Pseudomonas spp. [5] Plasmid-mediated resistance against some gram-negatives including A. baumannii and P. aeruginosa has been reported in burn patients [9, 18, 21] Reduced mortality in burned mice with P. aeruginosa infection by 60-75% [16] Poor correlation between broth microdilution and agar well diffusion [23] Triple antibiotic ointment (Neomycin, Polymyxin B, bacitracin)
Antimicrobial activity has been shown to reside in the neomycin component [52] Moderate activity against a variety of burn isolates, but has poor activity against P. aeruginosa [52] No data available No data available No data available None available b u r n s 3 6 ( 2 0 1 0 ) 1 1 7 2 -1 1 8 4 relatedness of ABC, MRSA, P. aeruginosa, and K. pneumoniae isolates was determined by PFGE as previously described using a CHEF-DRIII system (Bio-Rad Laboratories, Hercules, California) [27] [28] [29] . The endonuclease Apa I was used for ABC PFGE, Sma I for MRSA PFGE, Xba I for K. pneumoniae PFGE, and Spe I for P. aeruginosa PFGE. Gel images were analyzed using BioNumerics software (Applied Maths, Austin, TX). PFGE profiles were compared using the Dice coefficient and grouped into pulsed field types using established criteria [30] .
Broth microdilution assay
Minimum inhibitory concentrations (MIC) of tested compounds were determined using custom prepared 96-well MIC panels (Trek Diagnostic, Cleveland, OH), within the following concentration ranges: bacitracin, 0.12-256 mg/ml; mupirocin, 0.06-128 mg/ml; neomycin, 0.5-1024 mg/ml; polymixin B, 0.5-1024 mg/ml; silver nitrate, 0.12-256 mg/ml; silver sulfadiazine, 2-4096 mg/ml; mafenide acetate, 16-4096 mg/ml; and medical grade honey, 0-50%. The panels were thawed at room temperature and inoculated with a 95 pin disposable inoculator, according to the manufacturer's directions. To prepare the inoculum, fresh overnight cultures were suspended in sterile deionized water to meet a 0.5 McFarland standard. One milliliter of the cell suspension was pipetted into 29 ml of sterile deionized water and vortexed. The 30 ml cell suspension was poured into the inoculation tray and the 95 pin inoculator was placed into the inoculation tray with the empty pin spot aligned with the negative growth control well on the panel. The inoculators were then removed and discarded. The MIC panel was incubated at 37 8C for 24 h. After incubation, the panels were scored for growth. A button of 2 mm or larger was considered positive for growth. All isolates and drugs were tested in duplicate. If there was a greater than 2 dilution difference between each test for an individual isolate, the experiment was repeated. When reporting the data, the first run isolate that was within 2 dilutions of the other isolate was used. For each antimicrobial agent, the MIC 50 and MIC 90 were determined. The MIC 50 was defined as the minimum concentration required to inhibit growth of 50% of the isolates tested. Likewise, the MIC 90 was defined as the minimum concentration required to inhibit growth of 90% of the isolates tested. , and medical grade honey (Active Manuka Honey, USA). All of the antimicrobial agents except for silver nitrate were assayed using the Nathan agar well diffusion method [22] . The silver nitrate was tested by standard disk diffusion [31] . Briefly, 9 mm wells were made in Mueller-Hinton II agar plates using a sterile bore and then filled with 0.25 ml of antimicrobial agent. All of the wells were then sealed with 2-3 drops of 1.5% agar. The plates were inoculated using the agar overlay method [32] . Using fresh overnight cultures, a cell suspension was made in normal saline to make a 0.5 McFarland standard. A melted (45-50 8C) 9.0 ml 1.5% agar blank was then inoculated with 1 ml of the cell suspension, mixed gently by inversion, and then poured over the Mueller-Hinton agar plates. Once the agar overlay had solidified, 6 mm paper disks (BD BBL, Franklin Lakes, NJ) containing 10 ml of the silver nitrate solution were placed on the agar overlay. The plates were incubated for 24 h at 37 8C. Following incubation, the zones of inhibition were measured to the nearest millimeter. All agents and isolates were tested in duplicate. If there was a greater than 3 mm difference in zone size between the first and second test for a particular isolate, the experiment was repeated for that particular antimicrobial agent. When reporting data, the first run experiment with results within 3 mm of the other was reported. The average zone of inhibition size was calculated for each agent and reported as a mean and range.
Agar well diffusion
Results
Twenty isolates each of ABC, P. aeruginosa, and MRSA, and 22 isolates of K. pneumoniae from patients in the burn center were obtained from the hospital laboratory. Most of the isolates of each species were from a unique patient though one patient had two ABC isolates included. The isolates were from blood, skin and wounds, cerebrospinal fluid, and respiratory sites. The isolates were classified into clonal type based on pulsedfield gel electrophoresis data. ABC and P. aeruginosa were categorized as MDR or not based on susceptibilities to systemic antimicrobial agents (Tables 2-5 ). Forty-five percent of the P. aeruginosa isolates and 75% of the ABC isolates were categorized as MDR. All of the K. pneumoniae isolates were ESBL-producers. For each antimicrobial agent, the MIC 50 and MIC 90 were determined from the broth microdilution results and the mean zones of inhibition were calculated from the agar well diffusion (Tables 2-5 ). For MRSA (Table 2) , 18/20 isolates (90%) had MICs of >256 mg/ml to bacitracin and mafenide acetate had MICs ranging from 512 to 1024 mg/ml, with the MIC 50 and MIC 90 both 1024 mg/ml. Neomycin had wide range of MICs, from <0.5 to >1024 mg/ml. The topical antimicrobials containing silver, silver nitrate and silver sulfadiazine, had MICs ranging from 8 to 16 mg/ml with silver nitrate and from 32 to 64 mg/ml for silver sulfadiazine. Polymyxin B also had a moderate range of MICs, from 16 to 64 mg/ml, with MIC 50 of 16 mg/ml and MIC 90 of 32 mg/ml. The MICs for honey against MRSA ranged from 5 to 20 mg/ml. Mupirocin had the lowest range of MICs for MRSA, with MIC 50 of 1 mg/ml and MIC 90 of 2 mg/ml, making it the most active agent against MRSA by the broth microdilution method. Similarly, by the agar well diffusion method, mupirocin overall had very large zones of inhibition of 150 mm (the size of the plate) making it the topical agent with the best parameters for MRSA by both methods. Zones of inhibition for the silver-containing agents, again, were in the moderate range, with mafenide acetate and honey also falling into the moderate range by agar well diffusion. The diffusion zone for bacitracin was 9 mm for all isolates, meaning that the bacteria grew directly up to the well, since 9 mm is the size of the well. For 19/20 isolates (95%), the triple antibiotic ointment containing bacitracin, neomycin, and polymyxin B had diffusion zones of 9 mm. There were 7 different pulsed-field types (PFTs) among the 20 MRSA isolates, though there was generally no consistency among the types as to MICs, zones of inhibition, and antibiotic susceptibility profiles. The 2 isolates with lower bacitracin MICs were not the same PFT. One USA300 MRSA isolate had lower MICs to bacitracin, neomycin, and honey and a higher zone of inhibition to the triple antibiotic ointment, along with susceptibility to all systemic antibiotics tested. However, the other 4 USA300 clones did not show the same susceptibility profiles. Results differed somewhat for the gram-negative organisms, K. pneumoniae (Table 3) , P. aeruginosa (Table 4 ), and ABC ( Table 5) . For these organisms, bacitracin again had MICs >256 mg/ml, as did mafenide acetate. The MIC 50 for mafenide acetate for all organisms was 1024 mg/ml. Silver nitrate and silver sulfadiazine again had moderate MICs, as did honey. In contrast to MRSA, the MICs for mupirocin for the gram-negative organisms were all >128 mg/ml. For the gram-negatives, polymyxin B had low MICs, though MICs for neomycin to K. pneumoniae were even lower. Bacitracin again had zones of inhibition on agar well diffusion of 9 mm indicating growth right up to the well for all gramnegative isolates, as did most of the isolates against the triple antibiotic mix. The silver containing agents and honey had moderately sized zones of inhibition. Mafenide acetate had the largest average zone of inhibition against both P. aeruginosa and ABC (Tables 4 and 5) ; it also had a large zone of inhibition against K. pneumoniae however for that organism, mupirocin had the largest mean zone of inhibition (Table 3 ). There were no statistically significant correlations between MIC and zone of inhibition (for those agents where correlation could be performed) except for with P. aeruginosa and silver sulfadiazine, where the correlation was weakly negative at À0.65 ( p = 0.002) and with K. pneumoniae and mafenide, where the correlation was also weakly negative at À0.63 ( p = 0.002). It would be expected to see a negative correlation in this case as theoretically MICs should decrease with rising zones of inhibition. Overall, the P. aeruginosa and ABC isolates classified as MDR using the above definition did not appear to have more resistance to the topical antimicrobial agents than their non-MDR counterparts. As with MRSA, there was not consistency between PFT and susceptibility profile. The P. aeruginosa isolates with high MICs to neomycin were of different PFTs and did not result in any lower zones of inhibition with the triple antibiotic ointment. Only 2/3 of them were MDR. The same applies for ABC and neomycin, where isolates with the highest MICs to neomycin were of different PFTs, had the same zone of inhibition with the triple antibiotic ointment, and no significant difference in resistance to systemic antibiotics.
Discussion
In an era of increasing resistance to systemic antimicrobials necessitating use of second and third line and often more toxic agents, topical antimicrobial agents are an appealing choice for burn wound infections, given a theoretical decreased risk of systemic toxicities and the ability to position the antiinfective agent directly at the site of the infection, which is helpful in the setting of the avascularized tissue present in burn eschar [18] . In addition, early excision and grafting is not the standard of care worldwide and cannot always be performed even in our center due to delays in transport from austere settings to higher echelons of care. In that setting, topical agents can be very helpful as prophylaxis against burn wound infection. However, while we can easily obtain data about the susceptibility profiles of our commonly used systemic antibiotics, susceptibility information about topical agents is not readily available to help guide choice of topical therapy and furthermore, susceptibility breakpoints have not yet been standardized for these agents.
In this study we determined the susceptibility of topical antimicrobial agents against bacterial isolates of MRSA, ABC, ESBL-producing K. pneumoniae, and P. aeruginosa from burn patients using two previously described methods and compared these susceptibilities against the clonal type of the organism and susceptibility to systemic antimicrobial agents. We found that similar to previous studies, mafenide acetate is the most active agent overall against gram-negatives with mupirocin most active against MRSA. Silver had moderate efficacy as well, consistent with prior literature. Unlike other studies, however, we did not note increased resistance to topicals associated with MDR isolates vs. non-MDR isolates. Honey, which has not been evaluated using these techniques in the prior literature, had both moderate zones of inhibition and MICs against all of the isolates.
Both the agar well diffusion and broth microdilution methods have merits and flaws. Broth microdilution has been found to be more objective and reproducible than agar well diffusion. However, the agar well diffusion method requires the agents to diffuse in agar which takes into account their associated carriers, perhaps better mimicking the activity of these agents in burn eschar [22] . Neither method truly accounts for activity of the agents at the level of eschar and skin and further studies are needed to determine tissue levels.
We found that mupirocin had the best activity against MRSA, which is not surprising given prior studies on mupirocin. MICs were high and zones of inhibition were moderate against P. aeruginosa, which also corroborates with prior literature indicating that mupirocin is not an ideal antipseudomonal agent. Mafenide acetate was the best agent to cover all three gram-negative organisms by agar well diffusion though by MIC testing, it did not appear as effective. This has been described in prior studies. While it is concerning that mafenide acetate does not perform well in vitro, there have been multiple studies in vivo documenting its ability to diffuse through eschar so one might interpret the large zones of inhibition as more indicative of mafenide's performance in vivo [3, 5, 23, 33] . It is not surprising that zones of inhibition are scant for bacitracin, as it has been shown previously to not diffuse well through agar [23] . However, the high MICs also raise concern that these isolates were resistant even without the need to diffuse and raises concern about bacitracin being successfully used in this setting. The triple antibiotic ointment containing neomycin, polymyxin B, and bacitracin generally had low-to-moderate zones of inhibition with moderate-to-high MICs except in the case of K. pneumoniae. Neomycin has previously been noted to be the most active component of this triple therapy and so the fact that the neomycin has the lowest MICs against K. pneumoniae and the triple antibiotic ointment has the largest zone of inhibition with K. pneumoniae correlates well with prior reports that neomycin does not have good activity against P. aeruginosa. The results from honey's activity are interesting, in particular because honey is not an agent currently employed in our burn unit. By broth microdilution, honey had moderate MICs against all organisms, along with moderate zones of inhibition by agar well diffusion. Further research on the antimicrobial properties of honey to determine its spectrum and mechanism of action are needed as well as further standardization of medical grade (versus food grade) honey to ensure safety and reproducible outcomes.
As we move forward in treating burn patients with burn wound infections it will continue to be important to evaluate the appropriateness of our choices of topical antimicrobial therapy as increasing drug resistance ensues. Though our research did not show that MDR organisms had significantly different susceptibility profiles than non-MDR organisms, it was not designed to specifically show that difference since all of the S. aureus isolates were MRSA and all of the K. pneumoniae isolates were ESBL-producers. Future work could be performed to better evaluate whether susceptibility differences exist between MDR and non-MDR organisms in this setting. In addition, though we have substantial in vitro data describing the antimicrobial spectrum of activity of these agents, and we can get a sense of how they, in combination with their carriers, will diffuse in vivo by using the agar well diffuse method, at this point there is inadequate data describing how well these agents penetrate normal skin versus eschar in terms of their ability to obtain therapeutic drug levels. Further clinical studies with these agents and their carriers on skin and eschar are needed to ultimately determine standardized breakpoints so isolates can be classified as susceptible or resistant to topical agents. Bodies such as the Clinical and Laboratory Standards Institute (CLSI) should consider developing guidelines for use of topical agents.
Until we have gained further information, it seems reasonable to continue to use silver containing agents empirically for the prophylaxis of burn wound infection and mafenide acetate for the treatment of likely gram-negative burn wound infection. Mupirocin appear to be the best choice if MRSA infection is likely in a specific clinical setting. Bacitracin appears less effective using these methods while honey shows promise, although more clinical data are needed before making substantial changes to clinical practice. r e f e r e n c e s
